Trulicity ® (dulaglutid) injektion

För fullständig produktresumé för Trulicity® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Trulicity® (dulaglutid): Betacellfunktion vid utgångsläget

Behandling med dulaglutid resulterade i liknande minskningar av HbA1c-nivåer oavsett betacellsfunktion vid utgångsläget.

Post Hoc Analysis - Baseline Beta-Cell Function

A pooled post hoc analysis of 3 AWARD studies, AWARD-1, -3, and -6, was conducted to evaluate the effect of baseline beta-cell function on the glycemic response from dulaglutide treatment in patients with T2DM. Baseline beta-cell function was estimated by HOMA2-%B. Patients were categorized into 3 subgroups based on low, middle, or high baseline HOMA2-%B tertiles.1

After 26 weeks of treatment with dulaglutide and adjusting for differences in baseline HbA1c levels, the LSM reduction in HbA1c was similar across the 3 tertiles. The high-tertile baseline HOMA2-%B subgroup was noted with a greater numerical LSM reduction in HbA1c compared with the low-tertile baseline HOMA2-%B subgroup (Table 1).1,2

Table 1. Change in HbA1c Levels From Baseline to 26 Weeks Stratified by Tertiles of Baseline HOMA2-%B - Pooled Post Hoc Analysis From AWARD-1, -3, and -6 Studies1,2

HbA1c, %a 

DU 1.5 mg
Baseline HOMA2-%B Low
b
(n=293) 

DU 1.5 mg
Baseline HOMA2-%B Middle
c
(n=288)
 

DU 1.5 mg
Baseline HOMA2-%B High
d
(n=236)
 

DU 0.75 mge
Baseline HOMA2-%B Low
f
(n=147)
 

DU 0.75 mge
Baseline HOMA2-%B Middle
g
(n=171)
 

DU 0.75 mge
Baseline HOMA2-%B High
h
(n=211)
 

Change from baseline to 26 weeks 

-1.00
(-1.13,
-0.88)

-1.03
(-1.14,
-0.92)

-1.18
(-1.31,
-1.05)

-0.72
(-0.88,
-0.56)

-0.94
(-1.08,
-0.79)

-0.91
(-1.04,
-0.78)

Abbreviations: AWARD = Assessment of Weekly AdministRation of LY2189265 in Diabetes; DU = dulaglutide; HbA1c = glycated hemoglobin; HOMA2-%B = homeostasis model assessment 2 of beta-cell function; LSM = least squares mean.

a Data presented as LSM (95% CI).

b HOMA2-%B of 3.5% to 43.9%.

c HOMA2-%B of 44.2% to 73.9%.

d HOMA2-%B of 74.4% to 258.4%.

e Based on data from AWARD-1 and AWARD-3.

f HOMA2-%B of 4.6% to 43.8%.

g HOMA2-%B of 44.2% to 73.7%.

h HOMA2-%B of 74.4% to 463.5%.

References

1. Mathieu C, Del Prato S, Botros FT, et al. Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme. Diabetes Obes Metab. 2018;20(8):2023-2028. http://dx.doi.org/10.1111/dom.13313

2. Mathieu C, Botros FT, Thieu V, et al. Effect of once-weekly dulaglutide by baseline β-cell function in the AWARD program [abstract]. Diabetes. 2016;65(suppl 1):A269. http://diabetes.diabetesjournals.org/content/65/Supplement_1/A221

Glossary

AWARD = Assessment of Weekly AdministRation of LY2189265 in Diabetes

HbA1c = glycated hemoglobin

HOMA2-%B = homeostasis model assessment 2 of beta-cell function

LSM = least squares mean

T2DM = type 2 diabetes mellitus

Datum fӧr senaste ӧversyn 2018 M10 31


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss